Key Highlights

● CVM shares closed at $2.130 on October 7, 2026, a loss of 22.26% that erased roughly a fifth of the stock's value.

● No verified clinical trial result, regulatory decision, financing transaction, or Partnership development was identified as the catalyst.

● CEL-SCI is a long-running, pre-revenue clinical-stage biotech, a profile especially sensitive to shifts in risk appetite.

● The 10-year Treasury Yield reached roughly 5.35%, its highest since 2002, while the Russell 2000 led major indexes lower.

CEL-SCI (NYSE American:CVM) was among the notable decliners on the US market during the regular session of Wednesday, October 7, 2026, the most recently completed trading day. The shares closed at $2.130, a loss of 22.26% that erased roughly a fifth of the stock's value in a single session. For a clinical-stage biotechnology company, a move of this scale usually reflects a shift in how the market is pricing risk rather than a settled new fact.

A Long-Running Clinical Program Facing Sentiment Shifts

As of this writing there was no confirmed company-specific catalyst that clearly accounted for the drop. A targeted check did not surface a verified clinical trial result, regulatory decision, financing transaction, or partnership development dated to the session. CEL-SCI is a long-running, pre-revenue clinical-stage biotech, and names of that profile are among the most sensitive to changes in investor risk appetite.

Stock-Market Context

October 7 was a mild risk-off session in which the dominant force was a sharp rise in Treasury yields: the 10-year climbed to roughly 5.35%, its highest since 2002. Rising long-term rates are especially damaging to clinical-stage biotech, whose value rests entirely on cash flows that lie years in the future. The small-cap Russell 2000, home to many such names, led the major indexes lower with a loss of more than 1.3%.

Sentiment Shifting Ahead of Any Confirmed Data

The most defensible interpretation of CEL-SCI's October 7 decline is that it reflects biotech risk-off selling in a broadly risk-averse market, rather than a confirmed clinical or financial event. For a company pursuing its lead program for many years, sentiment can swing well ahead of any confirmed data.